Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

132.61
Delayed Data
As of 4:14pm ET
 -5.29 / -3.84%
Today’s Change
108.50
Today|||52-Week Range
194.73
-5.66%
Year-to-Date
Why Celator Pharmaceuticals Is Up 1,610% in 2016
8:23am / MotleyFool.com - Paid Partner Content
4 Cancer Drug Developers You Need to Have on Your Radar This Year
Jun 15 / MotleyFool.com - Paid Partner Content
Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Jun 15 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close137.90
Today’s open137.43
Day’s range131.24 - 137.50
Volume918,966
Average volume (3 months)789,631
Market cap$8.3B
Dividend yield--
Data as of 4:14pm ET, 06/27/2016

Growth & Valuation

Earnings growth (last year)+462.37%
Earnings growth (this year)+17.29%
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)+12.95%
P/E ratio25.1
Price/Sales6.69
Price/Book5.29

Competitors

 Today’s
change
Today’s
% change
RDYDr.Reddy's Laborator...+0.55+1.16%
IDXXIDEXX Laboratories I...-1.14-1.30%
MDVNMedivation Inc-0.34-0.60%
VRXValeant Pharmaceutic...-1.54-7.60%
Data as of 4:02pm ET, 06/27/2016

Financials

Next reporting dateAugust 2, 2016
EPS forecast (this quarter)$2.79
Annual revenue (last year)$1.3B
Annual profit (last year)$329.5M
Net profit margin24.87%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Bruce C. Cozadd
Chief Operating Officer &
Executive Vice President
Russell J. Cox
Corporate headquarters
Dublin, Dublin

Forecasts

Partner Offers

Search for Jobs